01 10Pulmozyme
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 774
2018 Revenue in Millions : 761
Growth (%) : 2
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 715
2019 Revenue in Millions : 837
Growth (%) : -15
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 609
2020 Revenue in Millions : 681
Growth (%) : -12
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 594
2021 Revenue in Millions : 609
Growth (%) : -3
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 524
2022 Revenue in Millions : 594
Growth (%) : -17
Main Therapeutic Indication : Rare Disease
Currency : USD
2014 Revenue in Millions : 4.40%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Rare Disease
Currency : USD
2015 Revenue in Millions : 603
2014 Revenue in Millions : 659
Growth (%) : 9%
Main Therapeutic Indication : Rare Diseases
Currency : USD
2016 Revenue in Millions : 678
2015 Revenue in Millions : 645
Growth (%) : 5
Main Therapeutic Indication : Rare Diseases
Currency : USD
2017 Revenue in Millions : 774
2016 Revenue in Millions : 726
Growth (%) : 7
Main Therapeutic Indication : Rare Diseases
Currency : USD
2018 Revenue in Millions : 746
2017 Revenue in Millions : 737
Growth (%) : 1%
